Unified Patent Court (UPC) analytics are now available. Check here

IP Verse

Mitsubishi Tanabe Pharma patent opposition analysis

Get Patent Opposition Report for Mitsubishi Tanabe Pharma

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Latest patents of Mitsubishi Tanabe Pharma opposed by its competitors

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent Number	Grant Date	Title	Total Oppositions
EP2896397	Oct 7, 2020	Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter	2
EP2252289	Oct 23, 2019	Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors	1
EP2754440	Apr 3, 2019	Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis	1
EP1714960	Mar 28, 2018	Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als	1

Top competitors of Mitsubishi Tanabe Pharma

MAIWALD

ELKINGTON AND FIFE

GALENICUM HEALTH SL